Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biopure delays US submission for blood substitute:

This article was originally published in Clinica

Executive Summary

Biopure has delayed by around six months plans to file a marketing application in the US for its blood substitute, Hemopure. The company previously said it would file a biologic licence application (BLA) for the product to the FDA by the end of 2001. The delay comes as a result of the company's plans to increase the production capacity of its Cambridge, Massachusetts manufacturing plant, a move that calls for additional facility and process validation requirements for the BLA filing. As a result, Biopure is targeting the filing for mid-2002 or sooner, depending on discussions with the FDA.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT074363

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel